Trial Search Results

A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma

This is a single-arm, open-label, multicenter, clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory ALCL.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Seagen Inc.

Collaborator: Millennium Pharmaceuticals, Inc.

Stanford Investigator(s):


  • Drug: brentuximab vedotin


Phase 2


Inclusion Criteria:

   - Patients with relapsed or refractory systemic ALCL who have previously received front
   line chemotherapy.

   - Documented anaplastic lymphoma kinase (ALK) status.

   - Histologically-confirmed CD30-positive disease; tissue from the most recent post
   diagnostic biopsy of relapsed/refractory disease must be available for confirmation of
   CD30 expression via slides or tumor block.

   - Fluorodeoxyglucose-avid and measurable disease of at least 1.5 cm as documented by
   both positron emission tomography and spiral computed tomography.

   - Received any previous autologous stem cell transplant at least 12 weeks (3 months)

   - At US sites, patients greater than or equal to 12 years of age may be enrolled. At
   non-US sites, patients must be greater than or equal to 18 years of age.

Exclusion Criteria:

   - Previous treatment with brentuximab vedotin.

   - Previously received an allogeneic transplant.

   - Patients with current diagnosis of primary cutaneous ALCL (patients who have
   transformed to systemic ALCL are eligible).

   - Known cerebral/meningeal disease.

Ages Eligible for Study

12 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Peds Hem/Onc CRAs
Not Recruiting